Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

Completed · Phase 2

Conditions studied: Allergic Conjunctivitis

In brief

To purpose of this study is to establish the efficacy and safety of RX-10045 ophthalmic solution in alleviating the signs and symptoms of allergic conjunctivitis

Key facts

Study ID

NCT01639846

Run by

C.T. Development America, Inc.

People needed

60

Starts

2012-07-01

Expected to finish

2012-08-01

Last updated by the study team

2013-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects MUST:
• Have a positive history of ocular allergies
• Have a positive bilateral conjunctival allergen challenge (CAC) reaction

You may not qualify if…

• Subjects MUST NOT:
• Have known contraindications or sensitivities to study medication or its components
• Have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters
• Use a disallowed medication during the period indicated prior to the enrollment or during the study
• Be a female who is currently pregnant, planning a pregnancy, lactating, or not using a medically acceptable form of birth control

Where it is running

• Andover Eye Associates — Andover, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.